tiprankstipranks
Trending News
More News >
CG Oncology, Inc. (CGON)
:CGON
US Market

CG Oncology, Inc. (CGON) AI Stock Analysis

Compare
164 Followers

Top Page

CG

CG Oncology, Inc.

(NASDAQ:CGON)

Rating:58Neutral
Price Target:
$27.00
▲(0.37%Upside)
CG Oncology, Inc.'s overall stock score is bolstered by positive corporate developments in its clinical trials, which enhance future growth prospects. However, the score is tempered by ongoing financial challenges and reliance on external funding. Technical indicators suggest moderate momentum, though the lack of revenue and negative valuation metrics remain concerning.
Positive Factors
Market Potential
There is confidence in creto's launch and uptake potential, which should outperform the early trajectory observed with other therapies.
Product Adoption
Creto is expected to be quickly adopted by urologists due to its familiar administration and convenient logistical profile.
Product Differentiation
Creto is meaningfully differentiated by its durability and safety data, which supports further upside for creto in additional indications and combinations with other therapies.
Negative Factors
Adverse Events
Durability for creto may be slightly more impressive but is awaiting further follow-up.
Clinical Concerns
Dr. Ghodoussipour was a bit hesitant on the higher frequency of grade 3+ TRAEs and discontinuations with TAR-200.
Competition
The bladder cancer landscape is large enough for multiple players, providing opportunities for creto even with new therapies expected to launch.

CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)

CG Oncology, Inc. Business Overview & Revenue Model

Company DescriptionCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
How the Company Makes MoneyCG Oncology, Inc. makes money primarily through the development and commercialization of its proprietary oncolytic immunotherapy treatments. The company's revenue model includes the potential for milestone payments, royalties, and licensing fees from partnerships with larger pharmaceutical companies. These partnerships may involve collaborative research and development agreements or licensing agreements for the distribution and marketing of CG Oncology's therapies. Additionally, the company may pursue direct commercialization of its products, subject to successful clinical trials and regulatory approval, to generate revenue through product sales.

CG Oncology, Inc. Financial Statement Overview

Summary
CG Oncology, Inc. is facing financial challenges typical of early-stage biotechnology firms, with no current revenue and significant operating losses. The strong equity position and cash reserves provide some stability, but the reliance on external funding indicates potential risks if capital markets shift. The company’s focus should be on achieving revenue growth and improving operational efficiencies to sustain long-term viability.
Income Statement
20
Very Negative
CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.
Balance Sheet
65
Positive
The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.
Cash Flow
30
Negative
The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue662.00K1.14M204.00K191.00K10.36M
Gross Profit655.00K1.14M204.00K176.00K10.35M
EBITDA-134.36M-114.63M-55.43M-35.23M-12.38M
Net Income-105.56M-88.04M-48.61M-35.44M-12.84M
Balance Sheet
Total Assets728.18M754.80M199.30M147.75M58.69M
Cash, Cash Equivalents and Short-Term Investments688.43M742.00M187.67M143.48M53.61M
Total Debt1.04M238.00K461.00K16.30M15.48M
Total Liabilities23.42M21.42M14.51M22.57M18.44M
Stockholders Equity704.76M733.38M184.79M125.18M40.25M
Cash Flow
Free Cash Flow-82.22M-78.95M-45.68M-29.82M-13.75M
Operating Cash Flow-81.98M-78.71M-45.68M-29.80M-13.65M
Investing Cash Flow-180.09M-300.76M-121.19M-55.35M-97.00K
Financing Cash Flow226.07M628.28M87.00M119.69M15.45M

CG Oncology, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price26.90
Price Trends
50DMA
25.69
Positive
100DMA
25.15
Positive
200DMA
29.32
Negative
Market Momentum
MACD
0.23
Negative
RSI
58.36
Neutral
STOCH
78.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 26.9 is above the 20-day moving average (MA) of 26.28, above the 50-day MA of 25.69, and below the 200-day MA of 29.32, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 58.36 is Neutral, neither overbought nor oversold. The STOCH value of 78.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Risk Analysis

CG Oncology, Inc. disclosed 81 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CG Oncology, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$2.05B-16.57%
57
Neutral
$5.79B25.71-31.22%5.61%10.88%-29.73%
MGMGX
52
Neutral
$62.43M-31.93%-4.22%18.67%
45
Neutral
$80.81M-196.81%
42
Neutral
$63.62M-38.04%
38
Underperform
$23.42M-559.73%
36
Underperform
$121.45M-49.72%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CGON
CG Oncology, Inc.
26.90
-5.14
-16.04%
FBLG
FibroBiologics, Inc.
0.61
-4.53
-88.13%
GUTS
Fractyl Health, Inc.
1.65
-2.67
-61.81%
ANRO
Alto Neuroscience, Inc.
2.35
-9.70
-80.50%
KYTX
Kyverna Therapeutics, Inc.
2.81
-4.84
-63.27%
MGX
Metagenomi, Inc.
1.67
-2.72
-61.96%

CG Oncology, Inc. Corporate Events

Executive/Board ChangesShareholder Meetings
CG Oncology Holds 2025 Annual Stockholders Meeting
Neutral
Jun 6, 2025

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CGON) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
CG Oncology Announces Promising Phase 3 Trial Results
Positive
Apr 28, 2025

On April 26, 2025, CG Oncology announced promising results from its Phase 3 BOND-003 clinical trial at the American Urological Association Annual Meeting. The trial data showed a 75.5% complete response rate at any time for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with cretostimogene grenadenorepvec. The 24-month complete response rate was 42.3%, with a median duration of response of 28 months. Additionally, 97.3% of patients remained free from progression to muscle-invasive disease, and the treatment was well-tolerated with no severe adverse events reported. Cohort P also showed a high-grade recurrence-free survival rate of 90.5% at 3 and 9 months. These results position cretostimogene as a potential breakthrough therapy for bladder cancer, offering distinct advantages over existing treatments.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025